In an industry driven by biomedical research advances, it is important for any investor to understand not only the science behind the product but also the scientific and disease specific implications of the product usage. At Celda consulting, we combine our extensive biomedical research experience with pharmaceutical and biotechnology market trends, regulatory and economic pressures influencing drug development to offer you advise on your biotechnology and pharmaceutical investments. From a comprehensive scientific review of pipeline drugs to evaluating preclinical development and clinical trial data, our team of experts can provide you invaluable technical insights into drug mechanisms, potency, and relevant genetic implications.

At Celda consulting we believe in the power of science to make informed decisions. Our team of highly experienced scientists can provide detailed analyses of drug effects in patient populations, identify susceptible populations, develop drug-DNA and drug-drug interactions and identify causative and compounding mechanisms for your mass tort and multi district litigations. Celda’s team of internationally published scientists has experience across a broad range of disciplines including, but not limited to cancer, cardiovascular, muscle, metabolic and genetic diseases, and immunology.

We offer comprehensive and fully customizable medical record review and analyses services to address your mass tort case requirements. We combine cutting edge technology with the expertise of skilled nurses and physicians to offer tailored solutions to your business needs.

Starting from medical record retrieval to detailed medical chronologies, summaries, medical opinions, and plaintiff fact sheets, you can choose from individual services or use our end to end medical record solutions for your mass torts.